Belharra Therapeutics emerged from stealth with a $50 million Series A financing from founding investor Versant Ventures. As a next-generation chemoproteomics company, Belharra’s platform is able to target any binding site, on any protein, in any cell type. undrugged proteome.
News
TIMELINE SINGLE TEMPLATE